NCT05608694|Active Not RecruitingDMC
Loading search results
Sponsor study identifier
interventional
250
1 country
2
Study Start
March 2, 2022
Actual (reported)Primary Completion
March 1, 2037
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 1, 2039
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The purpose of this study is to determine whether or not Magnetic Resonance Images (MRI) will identify high-grade cancers earlier and more frequently in men at high risk of developing prostate cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 1, 2039
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2, 2022
Actual (reported)October 10, 2022
Actual (reported)November 8, 2022
Actual (reported)March 1, 2037
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 1, 2039
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Proportion of patients with high grade prostate cancer detection.
MRI results will be collected every 3 years for 15 years until high grade prostate cancer is detected as defined as Gleason greater than or equal to 7 (Grade Group 2).
Every 3 years up to 15 years
Men who harbor known germline mutations that have been associated with an increased risk of prostate cancer and aggressive disease (e.g. BRCA2, ATM, PALB2, etc.) with or without a known family history of prostate cancer.
Men who harbor significantly increased disease risk based upon genetic risk score (GRS) value \>1.5 with or without a known family history of prostate cancer.
Group placement is determined by GRS score, Family history, and germline testing
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
University of Chicago
Chicago, Illinois, 60637, United States
NorthShore University Health System - Glenbrook Hospital
Glenview, Illinois, 60026, United States
Fazekas T, Shim SR, Basile G, Baboudjian M, Koi T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas JG, Gandaglia G, Szarvas T, Schoots IG, van den Bergh RCN, Leapman MS, Nyirady P, Shariat SF, Rajwa P. Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024 Jun 1;10(6):745-754. doi: 10.1001/jamaoncol.2024.0734.
Hugosson J, Godtman RA, Wallstrom J, Axcrona U, Bergh A, Egevad L, Geterud K, Khatami A, Socratous A, Spyratou V, Svensson L, Stranne J, Mansson M, Hellstrom M. Results after Four Years of Screening for Prostate Cancer with PSA and MRI. N Engl J Med. 2024 Sep 26;391(12):1083-1095. doi: 10.1056/NEJMoa2406050.
Abhinav Sidana, MD
University of Chicago
First Submitted
October 10, 2022
First Posted
November 8, 2022
Study Start
March 2, 2022
Actual (reported)Primary Completion
March 1, 2037
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Men with a family history of prostate cancer in at least one sibling, father, uncle, or grandfather but no known increased genetic risk of prostate cancer (has no pathogenic or likely pathogenic mutation along with a low genetic risk score (GRS\<1.5).
No known germline mutation, low genetic risk score (GRS \<1.5), and no known family history of prostate cancer.
Contact the study team to confirm eligibility.
Bjornebo L, Discacciati A, Falagario U, Vigneswaran HT, Jaderling F, Gronberg H, Eklund M, Nordstrom T, Lantz A. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial. JAMA Netw Open. 2024 Apr 1;7(4):e247131. doi: 10.1001/jamanetworkopen.2024.7131.
Study Completion
March 1, 2039
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 13, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: